Patents Assigned to Cybrexa 3, Inc.
  • Peptide conjugates of microtubule-targeting agents as therapeutics
    Patent number: 11555019
    Abstract: The present invention relates to peptide conjugates of microtubule-targeting agents such as maytansinoid derivatives which are useful for the treatment of diseases such as cancer.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: January 17, 2023
    Assignee: Cybrexa 3, Inc.
    Inventors: Daniel Richard Marshall, Johanna Marie Csengery, Robert John Maguire, Robert A. Volkmann